Amyloid B-Protein is a peptide that ranges in size from 28-43 amino acids. Most fragments have the same biological activity as the whole molecule. Amyloid B-Protein causes vascular and cerebral plaque formation. Insoluble fibrils of Amyloid B-Protein accumulate in adrenal blood vessels and un neutritic placques. Occurrence of placques are present in normal brain but in a much less dense degree as in Alzheimer’s disease patients. Amyloid B-Protein is also found in elevated levels in patients with Down’s Syndrome. Substance P has been found to counteract the effects of Amyloid B-Protein.
20- 80 pg/mL
Amyloid Protein is measured by a specific radioimmunoassay procedure that measures all fragments from 1-40 amino acids.
No specific patient preparation is required as Amyloid B-Protein is increased by the quantity and density of placques.
3mL EDTA plasma should be collected and separated as soon as possible. Freeze EDTA plasma immediately after separation. Minimum specimen size is 1 ml.
For tumor/tissue and various fluids (i.e. CSF, peritoneal, synovial, etc.) contact the Institute for requirements and special handling.
Ship specimens frozen in dry ice.
1. Whitson JS, Selkoe DJ and Cotman CW. Amyloid B-Protein enhances the survival of hippocampal neurons in vitro. Science 243: 1488-1490, 1989.
2. Yankner BA, Mesulam M-M. Beta-Amyloid and the pathogenesis of alzheimer’s disease. N Eng J Med 325: 1849-1857, 1991.